lundi 27 mai 2019

Onco Actu du 27 mai 2019


2. ETIOLOGIE



‘It’s killing us’: why firefighters are battling to ban flame retardants [The Guardian]











3.5 PRÉVENTION - UV



In rare occasions, dark-skinned people can get skin cancer. But sunscreens won’t help. [Washington Post]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Independent review of national cancer screening programmes in England -Interim report of emerging findings: Professor Sir Mike Richards [NHS England]










'Cancer screening should be as easy as booking a flight' [BBC News]











4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer [Qiagen]











4.12 BIOPSIES LIQUIDES



Multi-Site Study Tests Power of Commercial Reference Materials in Comparing Liquid Biopsy Assays [Genome Web]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



FLX Bio keeps it capital in RAPT Therapeutics rebrand [Fierce Biotech]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Dynavax axes immuno-oncology pipeline and 82 staff [Fierce Biotech]











Dynavax cuts staff in retreat from cancer research [Biopharma Dive]











Dynavax cuts staff and cancer R&D, focuses on vaccine [Pharmaforum]











5.2 PHARMA



FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [Novocure]











Novocure bags mesothelioma nod for electric fields cancer therapy with some limitations [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm [Fierce Pharma]











Ideaya wraps $50M IPO to fuel clinical drive on synthetic lethality [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Cancer research drives breast cancer treatment forward [Novartis]











FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer [Novartis]











FDA approves first PI3K inhibitor for breast cancer [FDA]











Make that 2 prospective blockbuster approvals in 1 day for Novartis as FDA OKs targeted cancer therapy [EndPoints]










Novartis' breast cancer treatment wins FDA approval [Reuters]











5.4 TRAITEMENTS - ECONOMIE



Novartis slaps $2M-plus price tag on newly approved gene therapy Zolgensma—and cost watchdogs approve [Fierce Pharma]











At $2.1 million, newly approved Novartis gene therapy will be world’s most expensive drug [STAT]










6.11 PATIENTS



‘I was a 31-year-old kid in a way’: How a cancer diagnosis changed a health care reporter [STAT]











6.4 MÉDICO-ÉCO



Measuring Financial Toxicity After Cancer Diagnosis and Treatment [ESMO]










6.9 CONTROVERSES



NHS bosses accused of breaking law in cancer scanning privatisation [The Guardian]